Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial.
Iyer G, Tangen CM, Sarfaty M, Regazzi AM, Lee IL, Fong M, Choi W, Dinney CPN, Flaig TW, Thompson IM Jr, Lerner SP, McConkey DJ, Rosenberg JE. Iyer G, et al. Among authors: flaig tw. JCO Precis Oncol. 2024 Nov;8:e2400287. doi: 10.1200/PO.24.00287. Epub 2024 Nov 5. JCO Precis Oncol. 2024. PMID: 39499893
Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial.
Plimack ER, Tangen C, Plets M, Kokate R, Xiu J, Nabhan C, Ross EA, Grundy E, Choi W, Dinney CPN, Lee IC, Fong M, Scott Lucia M, Daneshmand S, Theodorescu D, Goldkorn A, Lerner SP, Flaig TW, McConkey DJ. Plimack ER, et al. Among authors: flaig tw. Eur Urol. 2024 Oct;86(4):297-300. doi: 10.1016/j.eururo.2024.06.018. Epub 2024 Jul 14. Eur Urol. 2024. PMID: 39003201
NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024.
Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Buyyounouski MK, Chan K, Chang SS, Chang P, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kaimakliotis H, Kishan AU, Kundu S, Lele SM, Mamtani R, Mian OY, Michalski J, Montgomery JS, Parikh M, Patterson A, Peyton C, Plimack ER, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Stewart T, Sundi D, Tollefson M, Tward J, Wright JL, Cassara CJ, Gurski LA. Flaig TW, et al. J Natl Compr Canc Netw. 2024 May;22(4):216-225. doi: 10.6004/jnccn.2024.0024. J Natl Compr Canc Netw. 2024. PMID: 38754471
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab.
Milowsky MI, O'Donnell PH, Hoimes CJ, Petrylak DP, Flaig TW, Moon HH, Friedlander TW, Mar N, McKay RR, Srinivas S, Gravis G, Ramamurthy C, Bupathi M, Bracarda S, Wright P, Hepp Z, Carret AS, Yu Y, Dillon R, Kataria R, Beaumont JL, Purnajo I, Rosenberg JE. Milowsky MI, et al. Among authors: flaig tw. J Clin Oncol. 2024 Apr 20;42(12):1403-1414. doi: 10.1200/JCO.23.01547. Epub 2024 Jan 12. J Clin Oncol. 2024. PMID: 38215355 Free PMC article. Clinical Trial.
144 results